Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accenture Sees AI Solutions For IDMP Compliance, Trial Efficiency

40% Of Client Sites Studied Recruited Zero Patients

Executive Summary

AI could help companies comply with regulations like GDPR and IDMP, apart from optimizing clinical trial processes, Accenture’s managing director leading R&D analytics in North America says, as he lists cases where the firm drove cost savings.

You may also be interested in...



How Boehringer, Lilly Are Taming The GenAI Dragon For Regulatory, Commercial Content

Heads of AI, global commercial services and human pharma services at Boehringer and Eli Lilly discuss at a recent summit ways to use generative AI like ChatGPT for commercial and regulatory content while tackling challenges like data protection, hallucination and CXO buy-in

Doing It The Nike Way – Novartis, AstraZeneca On Making The Metaverse Work

From AstraZeneca’s training program for its representatives to Pfizer’s campaign to drive vaccination in Brazil, the industry is taking a leaf out of Nike’s playbook in adopting the metaverse. Novartis’ executive director and AZ’s director of learning discussed applications and challenges at a recent event.

Global R&D Heads Talk Superbugs, PROTACs And More

A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel